By The Life Science Report
Source: Streetwise Reports 11/21/2018
A distributor of the proprietary product places a third large order.
Avivagen Inc. (VIV:TSX.V) announced in a news release it just sold 2 metric tons (2 mT) of OxC-beta Livestock to UNAHCO, the life sciences corporation’s exclusive distributor of the product in the Philippines.
“UNAHCO has reaffirmed its intention of making quarterly purchases of OxC-beta Livestock, which has become a growing and recurring revenue stream for Avivagen,” the release noted. The product now is registered in the Philippines for use in all animals that eat feed, primarily swine and broiler poultry. It is shown to be an effective, economic alternative to antibiotics commonly found in livestock feeds, the company noted.
Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
With this order, UNAHCO has bought 7.2 metric tons so far this year and 9.1 metric tons since its first purchase in November 2016.
Avivagen noted that it continues to accelerate uptake of its OxC-beta Livestock product. Along with the Philippines, it is currently registered and available for purchase in Taiwan, Thailand and New Zealand.
Read what other experts are saying about:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
( Companies Mentioned: VIV:TSX.V,